国际眼科杂志
國際眼科雜誌
국제안과잡지
International Eye Science
2015年
9期
1525-1528
,共4页
邬一楠%周宏健%吴国海%易全勇
鄔一楠%週宏健%吳國海%易全勇
오일남%주굉건%오국해%역전용
Bevacizumab%兔眼%玻璃体腔%Tenon囊%注射%血清%药物浓度
Bevacizumab%兔眼%玻璃體腔%Tenon囊%註射%血清%藥物濃度
Bevacizumab%토안%파리체강%Tenon낭%주사%혈청%약물농도
bevacizumab%rabbit eye%vitreous cavity%Tenon capsule%injection%serum%drug concentration
目的：比较兔眼球后 Tenon 囊下灌注和玻璃体腔注射bevacizumab 后玻璃体和血清中的浓度,并观察bevacizumab 视网膜荧光显影,探讨 bevacizumab 球后Tenon囊下灌注的眼内通透性和眼外给药途径的可行性。方法：实验用健康成年新西兰兔20只,随机分为A组和B 组, A 组均单眼接受单次玻璃体腔注射1.25 mg bevacizumab(1.25mg/0.05mL),B组均单眼单次Tenon囊下灌注5 mg bevacizumab (5 mg/0.2 mL )。1、3 d 后抽取玻璃体和血液,使用双抗体夹心Elisa检测玻璃体和血清中bevacizumab药物浓度,比较两组中玻璃体和血清内bevacizumab浓度差异,并通过激光共聚焦观察视网膜免疫荧光。<br> 结果：给药1d后,A组和B组玻璃体腔内bevacizumab药物浓度分别为254.40依13.65、1.60依0.32μg/mL。 A组和B组血清内 bevacizumab 药物浓度分别为0.55依0.15、0.63依0.05μg/mL,两组血清 bevacizumab 浓度比较差异无统计学意义(t=1.168,P=0.277)。给药3d后,A组和B组玻璃体腔内 bevacizumab 药物浓度分别为236.80依8.70、1.40依0.23μg/mL,A组和B组血清内bevacizumab药物浓度分别为0.66依0.17、0.64依0.14μg/mL,两组血清内bevacizumab浓度比较差异无统计学意义( t=0.207,P=0.841),两种给药方式视网膜各层荧光分布均能明显显现。结论：给药1、3d 后玻璃体腔注药组在玻璃体腔内bevacizumab药物浓度要明显高于Tenon囊下灌注组,玻璃体腔内注射是较为有效的给药途径,而球后Tenon囊下灌注也能使bevacizumab进入玻璃体腔而且达到完全抑制VEGF活动所需的浓度(>500 ng/mL ),并能至少持续3d以上,两种给药方法在血清中均能检测到较高浓度的bevacizumab,且两者浓度差异无统计学意义( P>0.05),两种给药方式视网膜各层荧光分布均能明显显现,提示两种给药方式药物均能作用于视网膜各层。
目的：比較兔眼毬後 Tenon 囊下灌註和玻璃體腔註射bevacizumab 後玻璃體和血清中的濃度,併觀察bevacizumab 視網膜熒光顯影,探討 bevacizumab 毬後Tenon囊下灌註的眼內通透性和眼外給藥途徑的可行性。方法：實驗用健康成年新西蘭兔20隻,隨機分為A組和B 組, A 組均單眼接受單次玻璃體腔註射1.25 mg bevacizumab(1.25mg/0.05mL),B組均單眼單次Tenon囊下灌註5 mg bevacizumab (5 mg/0.2 mL )。1、3 d 後抽取玻璃體和血液,使用雙抗體夾心Elisa檢測玻璃體和血清中bevacizumab藥物濃度,比較兩組中玻璃體和血清內bevacizumab濃度差異,併通過激光共聚焦觀察視網膜免疫熒光。<br> 結果：給藥1d後,A組和B組玻璃體腔內bevacizumab藥物濃度分彆為254.40依13.65、1.60依0.32μg/mL。 A組和B組血清內 bevacizumab 藥物濃度分彆為0.55依0.15、0.63依0.05μg/mL,兩組血清 bevacizumab 濃度比較差異無統計學意義(t=1.168,P=0.277)。給藥3d後,A組和B組玻璃體腔內 bevacizumab 藥物濃度分彆為236.80依8.70、1.40依0.23μg/mL,A組和B組血清內bevacizumab藥物濃度分彆為0.66依0.17、0.64依0.14μg/mL,兩組血清內bevacizumab濃度比較差異無統計學意義( t=0.207,P=0.841),兩種給藥方式視網膜各層熒光分佈均能明顯顯現。結論：給藥1、3d 後玻璃體腔註藥組在玻璃體腔內bevacizumab藥物濃度要明顯高于Tenon囊下灌註組,玻璃體腔內註射是較為有效的給藥途徑,而毬後Tenon囊下灌註也能使bevacizumab進入玻璃體腔而且達到完全抑製VEGF活動所需的濃度(>500 ng/mL ),併能至少持續3d以上,兩種給藥方法在血清中均能檢測到較高濃度的bevacizumab,且兩者濃度差異無統計學意義( P>0.05),兩種給藥方式視網膜各層熒光分佈均能明顯顯現,提示兩種給藥方式藥物均能作用于視網膜各層。
목적：비교토안구후 Tenon 낭하관주화파리체강주사bevacizumab 후파리체화혈청중적농도,병관찰bevacizumab 시망막형광현영,탐토 bevacizumab 구후Tenon낭하관주적안내통투성화안외급약도경적가행성。방법：실험용건강성년신서란토20지,수궤분위A조화B 조, A 조균단안접수단차파리체강주사1.25 mg bevacizumab(1.25mg/0.05mL),B조균단안단차Tenon낭하관주5 mg bevacizumab (5 mg/0.2 mL )。1、3 d 후추취파리체화혈액,사용쌍항체협심Elisa검측파리체화혈청중bevacizumab약물농도,비교량조중파리체화혈청내bevacizumab농도차이,병통과격광공취초관찰시망막면역형광。<br> 결과：급약1d후,A조화B조파리체강내bevacizumab약물농도분별위254.40의13.65、1.60의0.32μg/mL。 A조화B조혈청내 bevacizumab 약물농도분별위0.55의0.15、0.63의0.05μg/mL,량조혈청 bevacizumab 농도비교차이무통계학의의(t=1.168,P=0.277)。급약3d후,A조화B조파리체강내 bevacizumab 약물농도분별위236.80의8.70、1.40의0.23μg/mL,A조화B조혈청내bevacizumab약물농도분별위0.66의0.17、0.64의0.14μg/mL,량조혈청내bevacizumab농도비교차이무통계학의의( t=0.207,P=0.841),량충급약방식시망막각층형광분포균능명현현현。결론：급약1、3d 후파리체강주약조재파리체강내bevacizumab약물농도요명현고우Tenon낭하관주조,파리체강내주사시교위유효적급약도경,이구후Tenon낭하관주야능사bevacizumab진입파리체강이차체도완전억제VEGF활동소수적농도(>500 ng/mL ),병능지소지속3d이상,량충급약방법재혈청중균능검측도교고농도적bevacizumab,차량자농도차이무통계학의의( P>0.05),량충급약방식시망막각층형광분포균능명현현현,제시량충급약방식약물균능작용우시망막각층。
AIM:To compare the concentration of Bevacizumab in serum and vitreous after bevacizumab administered by retrobulbar Tenon capsule perfusion and intravitreal injection in eyeballs of rabbits and observe the fluorescence of retinal, and to investigate the intraocular permeability of bevacizumab after retrobulbar Tenon capsule perfusion feasibility of extraocular administration route. <br> METHODS: Twenty healthy adult New Zealand rabbits were used in the study. The rabbits were randomly divided into two groups, group A received single administration of 1. 25mg bevacizumab ( 1. 25mg/0.05mL) by intravitreal injection, group B received single administration of 5mg bevacizumab ( 5mg/0. 2mL ) by retrobulbar Tenon capsule perfusion. Bevacizumab concentrations in serum and vitreous were determined by double antibody sandwich Elisa at 1 and 3d after administration. The changes of bevacizumab concentrations in serum and vitreous of two groups were compared, and the fluorescence of retinal was observed by laser confocal microscope. <br> RESULTS: One day after administration, intravitreal concentrations of bevacizumab in vitreous of group A and B were 254. 40 ± 13. 65 and 1. 60 ± 0. 32μg/mL respectively. Concentrations of bevacizumab in serum of group A and B were 0. 55±0. 15 and 0. 63±0. 05μg/mL respectively. The changes of bevacizumab concentrations in serum between two groups did not vary significantly ( t = 1. 168, P = 0. 277 ). At 3d after administration, concentrations of bevacizumab in vitre-ous of group A and B were 236. 80±8. 70 and 1. 40±0.23μg/mL respectively. Concentrations of bevacizumab in serum of group A and B were 0. 66±0.17μg/mL and 0.64 ± 0. 14μg/mL respectively. The changes of bevacizumab concentrations in serum between two groups did not vary significantly (t=0. 207, P=0. 841). For two administration routes, the fluorescence distribution of retina layers could be clearly detected. <br> CONCLUSION: At 1 and 3d after intravitreal injection, intravitreal concentrations of bevacizumab of group A is much higher than that of group B. Intravitreal injection of bevacizumab is the more effective route of administration for intraocular tissue. But retrobulbar Tenon capsule perfusion can also achieve the minimum concentration which can completely blocks VEGF activity (>500ng/mL), and can remain for at least three days. Both intravitreal injection and retrobulbar Tenon capsule perfusion of bevacizumab results in high serum concentration, and the change of bevacizumab concentration in serum between two groups does not vary significantly. In both administration routes, the fluorescence distribution of retina layers can be clearly detected, and both two dosing ways can work on each layer of retina.
